Analyst firms · BofA Securities · AKRO

BofA Securities AKRO price target and rating history

Akero Therapeutics Inc. (AKRO) · Health Care

BofA Securities rates Akero Therapeutics Inc. (AKRO) Buy with a $63 price target, as of its latest action on Jan 30, 2025. It has published 3 rating actions on AKRO since September 2021, including 1 upgrade and 0 downgrades.

Current rating
Buy
Price target
$63
Median target, all firms
Too few
Actions on AKRO
3

BofA Securities price target on AKRO

$63$47$3020222023202420252026
BofA Securities price target on AKRO, each point a stated target, September 2021 to January 2025.

Every BofA Securities rating on AKRO

Questions about BofA Securities and AKRO

What is BofA Securities's price target for AKRO?
BofA Securities's latest stated price target for Akero Therapeutics Inc. (AKRO) is $63, from its action on Jan 30, 2025.
What is BofA Securities's rating on AKRO?
BofA Securities rates AKRO Buy, a bullish rating, as of Jan 30, 2025.
When did BofA Securities last change its view on AKRO?
On Jan 30, 2025, BofA Securities upgrades to Buy from Neutral, price target $35 to $63.

More AKRO rating histories

All BofA Securities ratingsAKRO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.